A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.

Summary

This trial is a single-center, non-blind, two-arm randomized prospective controlled trial to compare the effectiveness of two induction chemotherapy regimens (high-dose cytarabine plus daunorubicin \[HDAC\] vs. cytarabine plus high-dose daunorubicin \[AD\]) in acute myeloid leukemia (AML). The primary hypothesis of the study is that AD is superior to HDAC in terms of event-free survival (EFS, time from registration to induction failure, relapse, or death).

Timeline

Start

2018-03-01

Primary completion

2028-12-31

Completion

2028-12-31

Drugs

Indications